Bruce N. Jacobs - 30 Jun 2026 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Reporting relationship: Chief Financial Officer
Issuer ticker: KYMR
Reported as of: 30 Jun 2026
Net transaction value: -$8,864,829
SEC form: 4
Accepted by SEC: 02 Jul 2026, 18:30:07 UTC
Prior SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Bruce N. Jacobs

Key filing fact

Bruce N. Jacobs filed Form 4 for Kymera Therapeutics, Inc. (KYMR) on 02 Jul 2026.

Key facts

This page summarizes Bruce N. Jacobs's Form 4 filing for Kymera Therapeutics, Inc. (KYMR).
10 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2026, 18:30.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: -$8,864,829.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001821074 Primary reporting owner

Jacobs Bruce N.

Relationship: Chief Financial Officer
Address: C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Signature: /s/ Bruce N. Jacobs
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KYMR transaction

Common Stock

Options Exercise

Transaction value
Shares: +61,378
Change %: +24%
Price: $5.33^*
Shares after: 321,992
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F2

KYMR transaction

Common Stock

Sale

Transaction value: $165,810
Shares: -1,500
Change %: -0.47%
Price: $110.54
Shares after: 320,492
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F3

KYMR transaction

Common Stock

Sale

Transaction value: $189,664
Shares: -1,700
Change %: -0.53%
Price: $111.57
Shares after: 318,792
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F4

KYMR transaction

Common Stock

Sale

Transaction value: $124,067
Shares: -1,100
Change %: -0.35%
Price: $112.79
Shares after: 317,692
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F5

KYMR transaction

Common Stock

Sale

Transaction value: $469,311
Shares: -4,110
Change %: -1.3%
Price: $114.19
Shares after: 313,582
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F6

KYMR transaction

Common Stock

Sale

Transaction value: $5,896,288
Shares: -51,375
Change %: -16%
Price: $114.77
Shares after: 262,207
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F7

KYMR transaction

Common Stock

Sale

Transaction value: $923,178
Shares: -7,971
Change %: -3%
Price: $115.82
Shares after: 254,236
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F8

KYMR transaction

Common Stock

Sale

Transaction value: $719,862
Shares: -6,153
Change %: -2.4%
Price: $116.99
Shares after: 248,083
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F9

KYMR transaction

Common Stock

Sale

Transaction value: $376,649
Shares: -3,200
Change %: -1.3%
Price: $117.70
Shares after: 244,883
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F10

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KYMR transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -61,378
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 30 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 61,378
Exercise price: $5.33
Footnotes: F1, F11

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 11 footnotes

Footnote F1

These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person.

Footnote F2

This number includes 373 shares acquired under the Registrant's employee stock purchase plan.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.37 to $110.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.41 to $112.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.49 to $113.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.49 to $114.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.49 to $115.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.49 to $116.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 to $118.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F11

The shares underlying this stock option are fully vested and exercisable.